← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT04838678

NCT04838678 Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04838678
Status Recruiting
Phase EARLY_Phase 1
Sponsor University of Texas Southwestern Medical Center
Condition Hypertension
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2021-07-18
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Neuropeptide Y

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 100 participants in total. It began in 2021-07-18 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.

Eligibility Criteria

Inclusion Criteria: * Control - BMI\<30, age 18-55 * Hypertensive - BMI\<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI\>30, age 18-55 Obese-hypertensive- BMI\>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Exclusion Criteria: All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,

Contact & Investigator

Central Contact

Christopher M Hearon, Ph.D.

✉ christopher.hearon@utsouthwestern.edu

📞 214-345-4624

Frequently Asked Questions

Who can join the NCT04838678 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT04838678 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT04838678 currently recruiting?

Yes, NCT04838678 is actively recruiting participants. Contact the research team at christopher.hearon@utsouthwestern.edu for enrollment information.

Where is the NCT04838678 trial being conducted?

This trial is being conducted at Dallas, United States.

Who is sponsoring the NCT04838678 clinical trial?

NCT04838678 is sponsored by University of Texas Southwestern Medical Center. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology